JOP20210166A1 - علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r - Google Patents

علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r

Info

Publication number
JOP20210166A1
JOP20210166A1 JOP/2021/0166A JOP20210166A JOP20210166A1 JO P20210166 A1 JOP20210166 A1 JO P20210166A1 JO P20210166 A JOP20210166 A JO P20210166A JO P20210166 A1 JOP20210166 A1 JO P20210166A1
Authority
JO
Jordan
Prior art keywords
cgrp
treatment
antibodies
medication overuse
overuse headache
Prior art date
Application number
JOP/2021/0166A
Other languages
English (en)
Inventor
Barbara Schaeffler
Lahar Mehta
Joseph Hirman
Jeffrey T L Smith
Roger K Cady
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20210166A1 publication Critical patent/JOP20210166A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بطريقة لعلاج أو الوقاية من الصداع الناتج عن فرط استعمال الأدوية. تضم الطرق التمثيلية إعطاء جسم مضاد مناهض لـCGRP لمريض بحاجة إلى ذلك
JOP/2021/0166A 2019-01-08 2020-01-08 علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r JOP20210166A1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US201962872983P 2019-07-11 2019-07-11
PCT/US2020/012790 WO2020146535A1 (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Publications (1)

Publication Number Publication Date
JOP20210166A1 true JOP20210166A1 (ar) 2023-01-30

Family

ID=71404208

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0166A JOP20210166A1 (ar) 2019-01-08 2020-01-08 علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r

Country Status (21)

Country Link
US (1) US20200216525A1 (ar)
EP (1) EP3908607A4 (ar)
JP (1) JP2022516957A (ar)
KR (1) KR20210114002A (ar)
CN (1) CN113272324A (ar)
AU (1) AU2020207299A1 (ar)
BR (1) BR112020018044A2 (ar)
CA (1) CA3123292A1 (ar)
CL (1) CL2021001813A1 (ar)
CO (1) CO2021008665A2 (ar)
DO (1) DOP2021000145A (ar)
EC (1) ECSP21052193A (ar)
IL (1) IL284677A (ar)
JO (1) JOP20210166A1 (ar)
MA (1) MA54709A (ar)
MX (1) MX2021008268A (ar)
NI (1) NI202100063A (ar)
PE (1) PE20211708A1 (ar)
SG (1) SG11202106878XA (ar)
TW (1) TW202030205A (ar)
WO (1) WO2020146535A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
ES2893073T3 (es) 2011-05-20 2022-02-07 H Lundbeck As Composiciones anti CGRP y uso de las mismas
DK2709662T3 (da) 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
AU2022333323A1 (en) * 2021-08-27 2024-02-29 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112723A2 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
ES2893073T3 (es) * 2011-05-20 2022-02-07 H Lundbeck As Composiciones anti CGRP y uso de las mismas
CN103585449B (zh) * 2013-10-23 2016-06-22 高丽丽 用于治疗偏头痛的中药组合物
MX2017013113A (es) * 2015-04-16 2018-07-06 Alder Biopharmaceuticals Inc Anticuerpos anti-pacap y sus usos.
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP2022516956A (ja) * 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Also Published As

Publication number Publication date
EP3908607A4 (en) 2022-10-05
CO2021008665A2 (es) 2021-07-19
TW202030205A (zh) 2020-08-16
CL2021001813A1 (es) 2021-12-24
US20200216525A1 (en) 2020-07-09
CN113272324A (zh) 2021-08-17
EP3908607A1 (en) 2021-11-17
WO2020146535A1 (en) 2020-07-16
IL284677A (en) 2021-08-31
PE20211708A1 (es) 2021-09-01
DOP2021000145A (es) 2021-10-31
KR20210114002A (ko) 2021-09-17
MX2021008268A (es) 2021-08-05
BR112020018044A2 (pt) 2021-08-10
NI202100063A (es) 2021-12-01
SG11202106878XA (en) 2021-07-29
ECSP21052193A (es) 2021-08-31
JP2022516957A (ja) 2022-03-03
CA3123292A1 (en) 2020-07-16
AU2020207299A1 (en) 2021-08-26
MA54709A (fr) 2022-04-13

Similar Documents

Publication Publication Date Title
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
JO3559B1 (ar) جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه
MX2023010900A (es) Anticuerpo anti-cd20 de tipo ii y usos del mismo.
CR20210373A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
NZ728265A (en) Methods to enhance organ transplant and antibody therapies
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
MX2017014396A (es) Tratamiento de mieloma multiple.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2022004291A (es) Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.